The Cell Therapy stream brings together cell therapy technical experts to collectively address the standards, strategies, and technologies driving robust development, testing, and production of cell-based therapies. The Cell Therapy Analytics program delves into regulatory guidance, CMC pitfalls, potency assay development, raw material characterization, and analytical innovations such as rapid release testing, flow cytometry, NGS, and mass spectrometry. The CMC and Manufacturing program spotlights automation, decentralized and point-of-care models, in vivo CAR T platforms, cost reduction, digital and AI-driven modernization, and manufacturing for next-generation modalities including iPSCs, NKs, gamma deltas, TILs, and tissue-engineered products. Case studies throughout provide actionable insight into scalable, compliant, and patient-focused cell therapy manufacturing.

Conferences Include:

Keynote & Featured Speakers:

Innovations in Downstream AAV Purification
Stephen Soltys, PhD, Chief Manufacturing Officer, Primera Genotech

Concept and Execution for an Enhanced Analytical Control Strategy Development and Execution for Autologous Cell Therapies
Stephan O. Krause, PhD, Executive Director Analytical Quality, BMS Cell Therapies

CMC for in vivo CAR T Manufacturing: Opportunities, Challenges, and the Road Ahead
Nripen Singh, PhD, Executive Director and Site Head, Process Development, TRD CGT, Novartis

Scaling CAR T: Lessons from a Commercial Manufacturing Launch
Xavier J. De Mollerat Du Jeu, PhD, Global Head Automation and Innovation, Cell Therapy Manufacturing, Legend Biotech Co.